Mark Alan Goldberg - 23 Jun 2022 Form 4 Insider Report for IDERA PHARMACEUTICALS, INC.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 23 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jun 2022, 16:31:13 UTC
Prior SEC filing: 30 Jun 2022
Next SEC filing: 05 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ Mark Alan Goldberg

Key filing fact

Mark Alan Goldberg filed Form 4 for IDERA PHARMACEUTICALS, INC. on 27 Jun 2022.

Key facts

This page summarizes Mark Alan Goldberg's Form 4 filing for IDERA PHARMACEUTICALS, INC..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Jun 2022, 16:31.

Change

Previous filing in this sequence was filed on 30 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDRA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +26,000
Change %
Price: $0.000000
Shares after: 26,000
Date: 23 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,000
Exercise price: $0.4561
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2022 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy.

Footnote F2

The options vest in full and become immediately exercisable on June 23, 2023 (first anniversary of the date of grant), subject to continued service as a director of the Issuer.